Novel interferon-β-induced gene expression in peripheral blood cells

Area of Science:

• Immunology
• Molecular Biology
• Genetics

Background:

• Type I interferons (IFNs) are crucial for treating viral, neoplastic, and inflammatory conditions.
• Interferon-stimulated genes (ISGs) are believed to mediate the clinical effects of IFNs.
• Current macroarray assays rely on genes identified from long-term cell lines, potentially missing crucial responses in primary cells.

Purpose of the Study:

• To discover genes selectively induced or repressed by interferon-beta (IFN-β) in primary peripheral blood mononuclear cells (PBMC).
• To identify novel ISGs and IFN-repressed genes (IRGs) for improved monitoring of IFN-β therapy.
• To validate findings in both cell models and ex vivo patient samples.

Main Methods:

• Whole blood was exposed to physiological concentrations of IFN-β.
• RNA was extracted from PBMC, reverse-transcribed, and analyzed using cDNA microarrays.
• Quantitative PCR (qPCR) and ex vivo validation in patient blood samples were performed.

Main Results:

• Microarray analysis identified 39 ISGs and 20 IRGs in IFN-β-treated PBMC.
• Six novel ISGs were discovered, including GTP cyclohydrolase 1 and squalene epoxidase.
• One novel IRG, CXCL1, was identified, along with known IRGs like IL-1β and CXCL8.
• Results were validated in PBMC, astrocytoma cells, and ex vivo patient samples.

Conclusions:

• The identification of novel ISGs and IRGs in primary PBMC provides a more comprehensive understanding of IFN-β action.
• These newly identified genes enhance the utility of macroarray assays for monitoring IFN responsiveness in clinical settings.
• This research contributes to optimizing IFN-based therapies by improving patient response monitoring.